Publication: Polifarmacia, interacciones farmacológicas y medicamentos potencialmente inapropiados en pacientes infectados por VIH que reciben tratamiento antirretroviral en la Comunidad de Madrid
Loading...
Files
Official URL
Full text at PDC
Publication Date
2022-01-13
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La esperanza de vida de las personas con VIH (PC-VIH) ha aumentado drásticamente desde que se dispone de tratamiento antirretroviral eficaz, y sigue mejorando. Como consecuencia de la mejora de la supervivencia, las PC-VIH en los países desarrollados están envejeciendo, lo que significa que pueden tener un mayor riesgo de padecer comorbilidades y de sufrir daños por la polifarmacia, riesgos que probablemente aumentan con la edad y la fragilidad fisiológica. Los principales problemas derivados de la polifarmacia incluyen el aumento del número de fármacos, la disminución de la adherencia a la medicación, el mayor riesgo de interacciones farmacológicas clínicamente relevantes, el uso de medicamentos potencialmente inapropiados y el aumento del riesgo de reacciones adversas a los medicamentos dando lugar a lesiones orgánicas, hospitalización, muerte y aumento de los costes sanitarios...
The life expectancy of HIV-infected individuals has dramatically increased since combination antiretroviral therapy has been available and continues to improve.As a consequence of improved survival, HIV-infected individuals in developed countries are growing older, meaning that they may be at higher risk of both comorbid diseases and harm from polypharmacy, risks that likely increase with age and physiologic frailty.Major concerns associated with polypharmacy include increased pill burden, decreased medication adherence, increased risk of clinically relevant drug-drug interactions, potentially inappropriate medications, and adverse drug reactions, including organ system injury, hospitalization, death, and rising treatment-related costs...
The life expectancy of HIV-infected individuals has dramatically increased since combination antiretroviral therapy has been available and continues to improve.As a consequence of improved survival, HIV-infected individuals in developed countries are growing older, meaning that they may be at higher risk of both comorbid diseases and harm from polypharmacy, risks that likely increase with age and physiologic frailty.Major concerns associated with polypharmacy include increased pill burden, decreased medication adherence, increased risk of clinically relevant drug-drug interactions, potentially inappropriate medications, and adverse drug reactions, including organ system injury, hospitalization, death, and rising treatment-related costs...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, Departamento de Farmacología, Farmacognosia y Botánica, leída el 05-10-2021